14th European Congress on Epileptology

The decision has been made to postpone the 14th ECE (Dates to be confirmed). We will be announcing the new dates in the near future.



Chairs’ Symposium: Precision medicine for patients with epilepsy – are we there yet?

Co-chairs: Eugen Trinka (Austria) & Margitta Seeck (Switzerland)

  • How genetic findings impact patients’ treatment and prognosis – Sarah Weckhuysen (Belgium)
  • New imaging tools will advance patients’ diagnosis and treatment to the next level – Serge Vulliemoz (Switzerland)
  • New avenues in drug development will have an impact on patients’ life – Wolfgang Löscher (Germany)
  • What is needed to bring advances in diagnosis and treatment to the population? – The global implementation gap – Samuel Wiebe (Canada)


Neurodegeneration and epilepsy 

Co-chairs: Eleonora Aronica (Netherlands) & Stephan Rüegg (Switzerland)

  • Neurodegenerative disorders and seizures – the epidemiological view – Ettore Beghi (Italy) 
  • The ABT of neurodegeneration: alpha synuclein, beta amyloid, and tau protein and their role in epileptogenesis – Katja Kobow (Germany)
  • Diagnosis – neuroimaging, CSF, EEG – Giovani Frisoni (Italy) 
  • Therapeutic challenges of treating patients with epilepsy and neurodegenerative disorders – Stephan Rüegg (Switzerland)
  • The birth of hyperexcitability in Alzheimer’s Disease – Jeffrey Noebels (USA)


Novel approaches to drug discovery

Co-chairs: Matthew Walker (United Kingdom) & Meir Bialer (Israel)

  • Why we need novel approaches – Heidrun Potschka (Germany)
  • Novel models of paediatric epilepsies – Stéphane Auvin (France)
  • Zebra fish as tools for personalised medicine – Peter de Witte (Belgium)
  • Use of gene networks and induced pluripotent stem cells in drug discovery – Michael Johnson (United Kingdom)


Is it possible to predict outcome in childhood epilepsies?

Co-chairs: Nicola Specchio (Italy) & Georgia Ramantani (Switzerland)

  • The role of genetics: where to start for understanding outcome – Ingrid Scheffer (Australia)
  • Disease modifying treatments: is there an option? – Nicola Specchio (Italy)
  • Prediction of outcome after epilepsy surgery: what can we learn from the virtual brain? – Fabrice Bartolomei (France)
  • How EEG, MRI and neuroimaging of brain networks can help? – Torsten Baldeweg (United Kingdom)
  • The sooner, the better – Georgia Ramantani (Switzerland)


Future therapies for epilepsy

Co-chairs: Reetta Kälviäinen (Finland) & Meir Bialer (Israel)

  • Update on new antiepileptic drugs in the pipeline – Meir Bialer (Israel)
  • Can we develop new therapies for therapy-resistant patients? – Matthew Walker (United Kingdom)
  • Impact of new regulatory guidelines on drug development approaches – Emilio Perucca (Italy)
  • Innovative treatments for orphan epilepsies, one at a time? – J Helen Cross (United Kingdom)
  • Update on new antiepileptic devices in the pipeline – Kristl Vonck (Belgium)
Developed by Aplia - Powered by eZ PublishInformasjonskapsler